Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis has introduced Mycofenolatmofetil Actavis, immediately after the patent expired in the UK, Netherlands, Germany, Sweden and Finland.
Subscribe to our email newsletter
Mycofenolatmofetil Actavis (mycophenolate mofetil) is the generic equivalent of Roche’s Cellcept, and is used with other medicines to lower the body’s immunity after heart, kidney or liver transplant.
Mycofenolatmofetil Actavis is available in 500mg tablets or 250mg capsules.
Actavis has already launched the product in Bulgaria, Iceland, Norway, Portugal, Romania and Slovakia, where no patent was in place.
Iceland-based Actavis develops, manufactures, and sells generic pharmaceuticals.